Renalytix Plc (NASDAQ:RNLX – Get Free Report) rose 3.9% on Friday . The stock traded as high as $0.30 and last traded at $0.30. 227,213 shares traded hands during trading, a decline of 86% from the average daily volume of 1,589,565 shares. The stock had previously closed at $0.29.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Renalytix in a report on Friday, July 12th.
Check Out Our Latest Report on Renalytix
Renalytix Stock Performance
Institutional Investors Weigh In On Renalytix
An institutional investor recently bought a new position in Renalytix stock. Levin Capital Strategies L.P. acquired a new stake in shares of Renalytix Plc (NASDAQ:RNLX – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 555,000 shares of the company’s stock, valued at approximately $128,000. Levin Capital Strategies L.P. owned about 0.72% of Renalytix at the end of the most recent quarter. 9.92% of the stock is currently owned by institutional investors.
Renalytix Company Profile
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.
Read More
- Five stocks we like better than Renalytix
- What Do S&P 500 Stocks Tell Investors About the Market?
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- NYSE Stocks Give Investors a Variety of Quality Options
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- Investing in the High PE Growth Stocks
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.